Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a type 2 diabetes application to follow in 2026.
Boehringer and Cue Biopharma to develop autoimmune therapies
Podcast: What’s next for the pharma tariffs?
FDA to review Regeneron’s sBLA for aflibercept injection 8mg
FDA approves Neurelis’ nasal spray for seizures
ACIP recommends GSK’s RSV vaccine for at-risk adults 50 to 59
Analysis
View More
Themes
View MoreEli Lilly and BigHat Biosciences ink AI antibody discovery deal
The agreement adds to Eli Lilly’s growing portfolio of AI-enabled drug discovery partnerships.
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
Digital health and digital therapeutics (DTx) services and providers for the pharmaceutical industry
GlobalData Reports
View More
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Google-backed Isomorphic Labs raises $600m to advance AI drug discovery
EU Health Data Space strikes a chord in EU harmonisation plans
Mastering compliance and copyright in healthcare and MedComms
AstraZeneca director says AI must be a “thought partner” in drug discovery